The antipsychotic clozapine has been shown to have superior efficacy to most other treatments for psychosis, especially where treatment-resistant schizophrenia has been diagnosed. Like all medications, clozapine has a number of well-recognised adverse effects, some of which can be fatal. Evidence also suggests that those for whom clozapine is the most suitable treatment option do not receive it because the doctor or health system views the risks as too great to prescribe. The provision of guidelines including innovative consumer and general practitioner resources regarding the ways to most safely monitor and manage people who are exposed to clozapine has the potential to increase the safe use of the product and also to provide potential prescribers with more confidence in using it. This paper outlines both the process for development and the final package produced by a large metropolitan District Health Board service in Auckland, New Zealand. This material was aimed at non-specialist prescribers as well as consumers and their family/carers and other supports.
Statistics from Altmetric.com
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.